Insider Buying: BlossomHill Therapeutics (NASDAQ:BLSM) CFO Purchases $11,200.00 in Stock

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) CFO Jason Keyes purchased 700 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average cost of $16.00 per share, with a total value of $11,200.00. Following the completion of the acquisition, the chief financial officer directly owned 700 shares in the company, valued at approximately $11,200. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

BlossomHill Therapeutics Trading Down 1.7%

Shares of BLSM opened at $16.24 on Thursday. BlossomHill Therapeutics, Inc. has a 52-week low of $15.25 and a 52-week high of $17.25.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.